Fibroblast growth factor receptor 3 (FGFR3) mutation in a verrucous epidermal naevus associated with mild facial dysmorphism

British Journal of Dermatology

Volumn 156, Issue 6, 2007, Pages 1353-1356

  Collin, B ^a,c   Taylor, I B ^b   Wilkie, A O M ^b   Moss, C ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NONE   (Canada)

Author keywords

Cutaneous mosaicism; Epidermal naevi; FGFR3 mutation

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ARTICLE; CASE REPORT; CELL CULTURE; DISEASE ASSOCIATION; FACE DYSMORPHIA; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; KERATINOCYTE; NEVUS; PRIORITY JOURNAL; SCHOOL CHILD; VERRUCOUS EPIDERMAL NEVUS;

CHILD; CRANIOSYNOSTOSES; FACIAL ASYMMETRY; FEMALE; HUMANS; MOSAICISM; NEVUS, PIGMENTED; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 34447098079     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07869.x     Document Type: Article

References (16)

1. Hafner C, van Oers JM, Vogt T et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006 116: 2201 7.
2. Meyers GA, Orlow SJ, Munro IR et al. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995 11: 462 4.
3. Wilkes D, Rutland P, Pulleyn LJ et al. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. J Med Genet 1996 33: 744 8.
4. Bellus GA, Bamshad MJ, Przylepa KA et al. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet 1999 85: 53 65.
5. Baker KM, Olson DS, Harding CO et al. Long term survival in typical thanatophoric dysplasia type 1. Am J Med Genet 1997 70: 427 36.
6. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975 6: 331 44.
7. Rannan-Eliya SV, Taylor IB, de Heer IM et al. Paternal origin of FGFR3 mutations in Muenke-type craniosynostosis. Hum Genet 2004 115: 200 7.
8. Paller AS, Syder AJ, Chan YM et al. Genetic and clinical mosaicism in a type of epidermal nevus. N Engl J Med 1994 331: 1408 15.
9. Moss C, Jones DO, Blight A, Bowden PE. A birthmark due to cutaneous mosaicism for a keratin 10 mutation. Lancet 1995 345: 596.
10. Terrinoni A, Puddu P, Didona B et al. A mutation in the V1 domain of K16 is responsible for unilateral palmoplantar verrucous nevus. J Invest Dermatol 2000 114: 1136 40.
11. Munro CS, Wilkie AO. Epidermal mosaicism producing localised acne: somatic mutation in FGFR2. Lancet 1998 352: 704 5.
12. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005 304: 417 31.
13. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999 23: 18 20.
14. Logie A, Dunois-Larde C, Rosty C et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumours in mice and humans. Hum Mol Genet 2005 14: 1153 60.
15. Hafner C, van Oers JM, Hartmann A et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006 126: 2404 7.
16. Hyland VJ, Robertson SP, Flanagan S et al. Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. Am J Med Genet 2003 120A: 157 68.